Literature DB >> 19850094

CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes.

Tatsuaki Tagami1, Kazuya Nakamura, Taro Shimizu, Naoshi Yamazaki, Tatsuhiro Ishida, Hiroshi Kiwada.   

Abstract

Gene therapy is largely dependent on the development of efficient delivery vehicles. To prolong their circulating time, PEGylation of the surface of a delivery vehicle is frequently applied. However, we have reported previously that anti-PEG IgM produced by intravenous injection of PEG-coated liposome is responsible for enhanced clearance of second dose PEG-coated liposomes, which is known as the "accelerated blood clearance (ABC) phenomenon." A similar phenomenon has been observed with PEG-coated pDNA-lipoplexes (PDCLs) upon their repeated injection. But the effect of the sequence of pDNA in PDCLs on inducing the ABC phenomenon has not been thoroughly investigated. Here, we focus on CpG motifs in pDNA, which are known to have a potent immune-stimulatory activity. PDCLs with non-CpG pDNA (PNDCL) diminished the anti-PEG IgM response, resulting in significant accumulation of a second dose in tumor tissue, comparable to that of a single injection, but not in enhanced accumulation in liver. In addition, PDCL induced proliferation of IgM(+) splenic cells including B cells. These results suggest that the CpG motif is a major cause of the induction of the ABC phenomenon when PDCLs are repeatedly injected. Immunogenicity is a relevant point of concern for non-viral delivery systems. Our results indicate that the use of non-CpG pDNA may allow meaningful repeated dosing of pDNA formulations without the induction of a strong immune reaction and thus may have important implications for therapeutic use of liposomal formulations of nucleic acids. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850094     DOI: 10.1016/j.jconrel.2009.10.017

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  19 in total

Review 1.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

Review 2.  Effect of surface properties on liposomal siRNA delivery.

Authors:  Yuqiong Xia; Jie Tian; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

3.  Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting.

Authors:  Shyh-Dar Li; Leaf Huang
Journal:  J Control Release       Date:  2010-03-23       Impact factor: 9.776

Review 4.  Polymersome-based drug-delivery strategies for cancer therapeutics.

Authors:  Tayebeh Anajafi; Sanku Mallik
Journal:  Ther Deliv       Date:  2015

5.  Nonadditive Effects of Repetitive Administration of Lipoplexes in Immunocompetent Mice.

Authors:  Jamie L Betker; Thomas J Anchordoquy
Journal:  J Pharm Sci       Date:  2016-11-22       Impact factor: 3.534

Review 6.  Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.

Authors:  K Laxmi Swetha; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 7.  Anti-PEG immunity: emergence, characteristics, and unaddressed questions.

Authors:  Qi Yang; Samuel K Lai
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-02-23

Review 8.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

Review 9.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.

Authors:  Jung Soo Suk; Qingguo Xu; Namho Kim; Justin Hanes; Laura M Ensign
Journal:  Adv Drug Deliv Rev       Date:  2015-10-09       Impact factor: 15.470

10.  Poly(2-oxazoline)s as materials for biomedical applications.

Authors:  Victor R de la Rosa
Journal:  J Mater Sci Mater Med       Date:  2013-08-23       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.